Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).
about
Small-molecule Bcl-2 antagonists as targeted therapy in oncologyTargeting Cell Survival Proteins for Cancer Cell DeathTreatment Strategies that Enhance the Efficacy and Selectivity of Mitochondria-Targeted Anticancer AgentsBcl-2 antagonists: a proof of concept for CLL therapyThe role of BH3-mimetic drugs in the treatment of pediatric hepatoblastomaTargeting the Bcl-2 family for cancer therapyTargeting Mcl-1 for the therapy of cancerTargeting the apoptosis pathway in hematologic malignanciesThe BH3 Mimetic Obatoclax Accumulates in Lysosomes and Causes Their AlkalinizationPotent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemiaEmerging Bcl-2 inhibitors for the treatment of cancer.Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance.Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapyEffect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine.BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells.Diversity-oriented synthesis: producing chemical tools for dissecting biology.A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia.Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells.Molecular interactions of prodiginines with the BH3 domain of anti-apoptotic Bcl-2 family membersOptimization of circulating biomarkers of obatoclax-induced cell death in patients with small cell lung cancer.SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destructionNovel small-molecule inhibitors of Bcl-XL to treat lung cancer.Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage.OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis.Sparse expression bases in cancer reveal tumor drivers.Small molecule inhibitors of bcl-2 family proteins for pancreatic cancer therapyThe Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment.Obatoclax regulates the proliferation and fusion of osteoclast precursors through the inhibition of ERK activation by RANKLSimultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death.Optical properties of prodigiosin and obatoclax: action spectroscopy and theoretical calculations.Rational Combinations of Targeted Agents in AMLNHE9 induces chemoradiotherapy resistance in esophageal squamous cell carcinoma by upregulating the Src/Akt/β-catenin pathway and Bcl-2 expression.Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent processTargeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibitionCDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis.Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review.Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members
P2860
Q24646161-F3D195DA-BD6F-4A14-8179-23695D6AAC0FQ26765447-7396E036-8CFC-498B-BD68-7C7B8D69AE45Q26800890-A5CEFAAF-236F-4389-AAAF-42162949AC12Q26823996-9CFE8E09-BF41-415E-B9AF-3385A493149DQ26827928-7F6956A2-4F9B-406E-8D98-0F2F101E8B2CQ26866936-606E3993-C2D1-4839-A126-0426813271FFQ27011870-11F4DAA5-EBF6-4FCD-9098-BC526B55134FQ27024422-A3CC7750-D0A2-4E1E-A8E5-7B10C2970F78Q27318794-E2E534A8-31EE-4F76-967E-8C2FA037D532Q30538418-548995E0-5852-40A9-A99F-24E8A49D4F83Q33682689-BE9240EF-8FF9-4D4C-9C98-2520E35F517EQ33755338-4D98980A-4829-4B5E-B5BB-D87C1489E25BQ33840360-FC0BBEFB-D0D7-4AC1-93DC-B658E083C005Q33989217-8AE84F6F-DEC3-4AB3-9C95-EC6785B87BE4Q34004454-CEDE7B61-F6F6-4BFA-AE0A-31B31377D733Q34074715-67D83C54-5847-4B49-AF3A-0CDABF8EB354Q34168014-CFD3E29E-418D-415F-A5EB-1E4B4609A9A4Q34227440-67DDD848-BBA7-4B7F-934D-63552F6C90D9Q34294097-C0C8B755-0585-40F9-B8CB-F780C34CF49DQ34309934-F5DECBB8-9D58-43E4-AA72-5AA038EE064CQ34608671-09F4DB15-A3D0-469A-86F9-A4F47360D9FFQ34763661-B192A72D-2FC4-43F7-9CCA-BBD6BBC4D3CAQ34788849-314CD9D1-9BC1-45B9-BEBF-F16642582DEEQ34793542-31424164-B334-47D7-A245-D64645536C78Q35007971-FD2C85CD-E90D-4099-B8A6-26DE50EE2A4DQ35075657-943A1CBE-631C-46DB-ACD2-D6A89ADC9639Q35088941-6AE88322-B028-49BE-BC3B-DC51E7B8A891Q35099238-284D67AB-DAA5-46FA-BEB8-84E29AFF84CBQ35180339-216E67F4-1460-40BD-B045-C8BC50F15414Q35188522-272E5DAF-DC53-4750-AFD4-9437629AC082Q35592015-FA25EA71-C444-41A2-B3E7-6D45C51D0DE2Q35676827-6B6E00BC-F38B-4AD4-BE81-6E7E5F50136EQ35750491-F1426707-6B4A-4794-8071-B4873BC04BF4Q35828588-8821E445-39F9-4541-AEC3-32A40912CD1DQ36057887-ABA1E557-49D6-4C6F-971C-E8F0488DD217Q36169778-469BCB5B-5170-4527-AAD4-5C470F709E14Q36170136-7957773C-8427-461D-B45C-CF63AFEA1173Q36284637-FF93330C-089A-42DE-BEA9-8477CD0F2DA1Q36541458-F0846BF3-AC42-48B7-9D26-952DE1763C3EQ36601134-4693AADC-99B0-4988-9AF5-0770A305B7FE
P2860
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Mechanisms of antileukemic act ...... mimetic GX15-070 (obatoclax).
@ast
Mechanisms of antileukemic act ...... mimetic GX15-070 (obatoclax).
@en
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070
@nl
type
label
Mechanisms of antileukemic act ...... mimetic GX15-070 (obatoclax).
@ast
Mechanisms of antileukemic act ...... mimetic GX15-070 (obatoclax).
@en
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070
@nl
prefLabel
Mechanisms of antileukemic act ...... mimetic GX15-070 (obatoclax).
@ast
Mechanisms of antileukemic act ...... mimetic GX15-070 (obatoclax).
@en
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070
@nl
P2093
P2860
P50
P1433
P1476
Mechanisms of antileukemic act ...... mimetic GX15-070 (obatoclax).
@en
P2093
David Harris
Ismael Samudio
Jean Viallet
Julie Watt
Rooha Contractor
William Bornmann
P2860
P304
P356
10.1158/0008-5472.CAN-07-1919
P407
P577
2008-05-01T00:00:00Z